» Articles » PMID: 36294421

Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Oct 27
PMID 36294421
Authors
Affiliations
Soon will be listed here.
Abstract

Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab affected its efficacy. The correlation between weight change and nutritional status up to the start of nivolumab treatment and OS and progression-free survival (PFS) after starting nivolumab treatment was determined. Nutritional status was examined using the C-reactive protein/albumin ratio (CAR). A loss in body weight (LBW) from the onset of the first treatment of <4.5% led to OS prolongation and improved PFS outcomes. The median OS values in the LBW < 4.5% and ≥4.5% groups were 11.4 and 3.6 months, respectively. Similarly, changes in CAR from first-line chemotherapy (ΔCAR) affected OS; the ΔCAR < 0.01 group had a better prognosis than the ΔCAR ≥ 0.01 group. The median OS values in the ΔCAR < 0.01 and ≥0.01 groups were 9.4 and 4.5 months, respectively. The median OS in the group with LBW < 4.5% and ΔCAR < 0.01 was 12.9 months. LBW and deterioration of nutritional status following first-line chemotherapy are poor prognostic factors in AGC patients who received nivolumab as third- or later-line therapy. Early intervention to maintain body weight and nutritional status may improve the efficacy of immune checkpoint inhibitors.

Citing Articles

Exploring the optimal indicator of short-term peridiagnosis weight dynamics to predict cancer survival: A multicentre cohort study.

Yin L, Zhang L, Li L, Liu M, Zheng J, Xu A J Cachexia Sarcopenia Muscle. 2024; 15(3):1177-1186.

PMID: 38644549 PMC: 11154758. DOI: 10.1002/jcsm.13467.


The Clinical Impact of Change in the C-Reactive Protein/Albumin Ratio in Gastric Cancer Patients Who Receive Curative Treatment.

Aoyama T, Maezawa Y, Hashimoto I, Hara K, Komori K, Otani K J Gastrointest Cancer. 2023; 55(1):383-390.

PMID: 37784000 PMC: 11096194. DOI: 10.1007/s12029-023-00970-z.


Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil.

Hashimoto I, Kano K, Onuma S, Suematsu H, Nagasawa S, Kanematsu K J Pers Med. 2023; 13(6).

PMID: 37373912 PMC: 10303086. DOI: 10.3390/jpm13060923.

References
1.
Mizukami T, Hamaji K, Onuki R, Yokomizo A, Nagashima Y, Takeda H . Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment. Nutr Cancer. 2021; 74(2):539-545. DOI: 10.1080/01635581.2021.1902542. View

2.
Yu J, Liu H, Zeng X, Zhao Y, Jiang D, Lu H . Prognostic and clinicopathological significance of C-reactive protein/albumin ratio (CAR) in patients with gastric cancer: A meta-analysis. PLoS One. 2021; 16(4):e0250295. PMC: 8075248. DOI: 10.1371/journal.pone.0250295. View

3.
Ikoma T, Shimokawa M, Matsumoto T, Boku S, Yasuda T, Shibata N . Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab. Cancer Immunol Immunother. 2022; 72(2):427-435. PMC: 10992512. DOI: 10.1007/s00262-022-03265-7. View

4.
Kudou K, Nakashima Y, Haruta Y, Nambara S, Tsuda Y, Kusumoto E . Comparison of Inflammation-Based Prognostic Scores Associated with the Prognostic Impact of Adenocarcinoma of Esophagogastric Junction and Upper Gastric Cancer. Ann Surg Oncol. 2020; 28(4):2059-2067. DOI: 10.1245/s10434-020-08821-y. View

5.
Fujii H, Makiyama A, Iihara H, Okumura N, Yamamoto S, Imai T . Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer. Anticancer Res. 2020; 40(12):7067-7075. DOI: 10.21873/anticanres.14734. View